TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SF7VV31
| Delayed Deutsche Boerse AG 02:28:00 05/06/2024 pm IST | ||
| 23.87 EUR | -0.13% |
|
| Current month | +8.24% | ||
| 1 month | +35.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 23.87 | -0.13% |
| 04/24/04 | 23.9 | +3.46% |
| 03/24/03 | 23.1 | +4.62% |
| 31/24/31 | 22.08 | +5.70% |
| 30/24/30 | 20.89 | -1.09% |
Delayed Quote Deutsche Boerse AG
Last update June 05, 2024 at 02:28 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7VV3 |
| ISIN | DE000SF7VV31 |
| Date issued | 18/08/2021 |
| Strike | 217.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.96 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.9 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.27 € |
| Spread % | 1.12% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
463.5
USD
Spread / Average Target
-2.41%
- Stock Market
- Certificates
- Certificat
